BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 24828988)

  • 1. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
    Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
    BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J; Gopalacharyulu P; Bian H; Hyötyläinen T; Leivonen M; Jaser N; Juuti A; Honka MJ; Nuutila P; Olkkonen VM; Oresic M; Yki-Järvinen H
    Diabetes; 2014 Jan; 63(1):312-22. PubMed ID: 24009255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
    Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
    Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
    Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
    Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
    J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.
    Mancina RM; Matikainen N; Maglio C; Söderlund S; Lundbom N; Hakkarainen A; Rametta R; Mozzi E; Fargion S; Valenti L; Romeo S; Taskinen MR; Borén J
    J Clin Endocrinol Metab; 2015 May; 100(5):E821-5. PubMed ID: 25763607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation.
    Franko A; Merkel D; Kovarova M; Hoene M; Jaghutriz BA; Heni M; Königsrainer A; Papan C; Lehr S; Häring HU; Peter A
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans.
    Kovarova M; Königsrainer I; Königsrainer A; Machicao F; Häring HU; Schleicher E; Peter A
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1568-74. PubMed ID: 26439088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.
    Valenti L; Nobili V; Al-Serri A; Rametta R; Leathart JB; Zappa MA; Dongiovanni P; Fracanzani AL; Alterio A; Roviaro G; Daly AK; Fargion S; Day CP
    J Hepatol; 2011 Dec; 55(6):1409-14. PubMed ID: 21777557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.
    Valenti L; Rumi M; Galmozzi E; Aghemo A; Del Menico B; De Nicola S; Dongiovanni P; Maggioni M; Fracanzani AL; Rametta R; Colombo M; Fargion S
    Hepatology; 2011 Mar; 53(3):791-9. PubMed ID: 21319195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
    Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
    Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
    Valenti L; Al-Serri A; Daly AK; Galmozzi E; Rametta R; Dongiovanni P; Nobili V; Mozzi E; Roviaro G; Vanni E; Bugianesi E; Maggioni M; Fracanzani AL; Fargion S; Day CP
    Hepatology; 2010 Apr; 51(4):1209-17. PubMed ID: 20373368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.
    Zampino R; Coppola N; Cirillo G; Boemio A; Grandone A; Stanzione M; Capoluongo N; Marrone A; Macera M; Sagnelli E; Adinolfi LE; del Giudice EM
    Dig Dis Sci; 2015 Oct; 60(10):3005-10. PubMed ID: 25986529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.